The IDH gene(s) mutation(s) in AML leads to intracellular oncometabolite 2-hydroxyglutarate (2-HG) accumulation in LSCs/blasts, leading to an altered DNA methylation pattern and increased LSCs persistence due to differentiation blockade, eventually leads to a poor prognosis. Here, IDH1 is linked to acute myeloid leukemia.